A Suggested Modification to FIGO Stage IV Epithelial Ovarian Cancer

被引:5
作者
Metairie, Marie [1 ]
Benoit, Louise [1 ,2 ]
Koual, Meriem [1 ,2 ]
Bentivegna, Enrica [1 ]
Wohrer, Henri [1 ]
Bolze, Pierre-Adrien [3 ]
Kerbage, Yohan [4 ]
Raimond, Emilie [5 ]
Akladios, Cherif [6 ]
Carcopino, Xavier [7 ]
Canlorbe, Geoffroy [8 ,9 ,10 ]
Uzan, Jennifer [11 ]
Lavoue, Vincent [12 ]
Mimoun, Camille [13 ]
Huchon, Cyrille [13 ,16 ]
Koskas, Martin [14 ]
Costaz, Helene [15 ]
Margueritte, Francois [16 ]
Dabi, Yohann [17 ]
Touboul, Cyril [17 ]
Bendifallah, Sofiane [17 ]
Ouldamer, Lobna [15 ,18 ]
Delanoy, Nicolas [19 ]
Nguyen-Xuan, Huyen-Thu [1 ]
Bats, Anne-Sophie [1 ,20 ,21 ]
Azais, Henri [1 ,20 ,21 ]
机构
[1] Hop Europeen Georges Pompidou, Assistance Publ Hop Paris AP HP, Dept Gynaecol Oncol & Breast Surg, F-75015 Paris, France
[2] Univ Paris Cite, Ctr Univ St Peres, INSERM UMR S 1124, F-75006 Paris, France
[3] Univ Lyon 1, Lyon Sud Univ Hosp, Dept Gynaecol & Oncol Surg & Obstet, Hosp Civils Lyon, F-69002 Lyon, France
[4] Univ Lille, Dept Gynaecol Surg, CHU Lille, F-59000 Lille, France
[5] Inst Alix Champagne Univ Hosp, Dept Obstet & Gynaecol, F-51100 Reims, France
[6] Hop Univ Strasbourg, Dept Gynaecol, F-67200 Strasbourg, France
[7] Aix Marseille Univ AMU, Univ Avignon, Hop Nord, Dept Obstet & Gynaecol, F-13397 Marseille, France
[8] Pitie Salpetriere, Assistance Publ Hop Paris AP HP, Dept Gynaecol & Breast Surg & Oncol, F-75013 Paris, France
[9] Sorbonne Univ, Ctr Rech St Antoine CRSA, Canc Biol & Therapeut, INSERM UMR S 938, F-75012 Paris, France
[10] Sorbonne Univ, Univ Inst Canc, F-75013 Paris, France
[11] Univ Paris Est Creteil, Ctr Hosp Intercommunal Creteil, Dept Obstet Gynecol & Reprod Med, F-94000 Creteil, France
[12] Univ Rennes 1, Hop Sud, Dept Gynaecol Surg, equipe 8, F-35000 Rennes, France
[13] Univ Paris, Hop Lariboisiere, Dept Gynaecol Oncol & Breast Surg, F-75010 Paris, France
[14] Hop Xavier Bichat, Assistance Publ Hop Paris AP HP, Div Gynaecol Oncol, F-75018 Paris, France
[15] Georges Francois Leclerc Ctr, Dept Surg Oncol, F-21000 Dijon, France
[16] Ctr Hosp Intercommunal Poissy St Germain en laye, Dept Gynaecol, Site Hosp Poissy, F-78498 Poissy, France
[17] Hop Tenon, AP HP Assistance Publ Hop Paris, Dept Gynaecol ans Obstet, F-75020 Paris, France
[18] Hop Univ Tours, Dept Gynaecol, F-37000 Tours, France
[19] Hop Europeen Georges Pompidou, AP HP Assistance Publ Hop Paris, Dept Med Oncol, F-75015 Paris, France
[20] Univ Paris Cite, Ctr Rech Cordeliers, INSERM UMR S 1147, F-75006 Paris, France
[21] Inst Canc Paris CARPEM, F-75006 Paris, France
关键词
epithelial ovarian cancer; FIGO stage IV; metastatic patterns; prognosis; pleural involvement; overall survival; FALLOPIAN-TUBE; CLASSIFICATION; SURVIVAL; DISEASE; IMPACT; RECOMMENDATIONS; CYTOREDUCTION; COMPLICATIONS; METASTASES; PATHOLOGY;
D O I
10.3390/cancers15030706
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Simple Summary The identification of prognostic factors is important to improve the management of patients with ovarian cancer (OC). The staging classification of OC was revised in 2014 and 2018 by the FIGO (International Federation of Gynecology and Obstetrics) Gynecological Oncology Committee and dichotomizes stages IV into stage IVA and IVB. The FIGO classification aims to establish a disease severity scale and to group patients with similar prognoses. The objective of our retrospective, multicenter study was to assess the prognostic impact of this dichotomization and of the initial metastatic localization of patients with FIGO stage IV OC. We showed that, among our 307 patients, FIGO stage IVA patients had a worse prognosis than FIGO stage IVB patients. The initial pleural effusion was a factor of poor prognosis in terms of overall survival. We suggest a modification of the current FIGO staging classification. International Federation of Gynecology and Obstetrics (FIGO) staging classification for stage IV epithelial ovarian cancer (EOC) separates stages IVA (pleural effusion) and IVB (parenchymal and/or extra-abdominal lymph node metastases). We aimed to evaluate its prognostic impact and to compare survival according to the initial metastatic location. We conducted a multicenter study between 2000 and 2020, including patients with a FIGO stage IV EOC. Primary endpoint was overall survival (OS). The secondary endpoints were progression-free survival (PFS) and recurrence rates. We included 307 patients: 98 (32%) had FIGO stage IVA and 209 (68%) had FIGO stage IVB. The median OS and PFS of stage IVA patients were significantly lower than those of stage IVB patients (31 versus 45 months (p = 0.02) and 18 versus 25 months (p = 0.01), respectively). Recurrence rate was higher in stage IVA than IVB patients (65% versus 47% (p = 0.004)). Initial pleural involvement was a poor prognostic factor with a median OS of 35 months versus 49 months for patients without initial pleural involvement (p = 0.024). Patients with FIGO stage IVA had a worse prognosis than patients with FIGO stage IVB EOC. Pleural involvement appears to be relevant for predicting survival. We suggest a modification of the current FIGO staging classification.
引用
收藏
页数:12
相关论文
共 50 条
  • [41] Paclitaxel/carboplatin versus topotecan/paclitaxel/carboplatin in patients with FIGO suboptimally resected stage III-IV epithelial ovarian cancer a multicenter, randomized study
    Bolis, Giorgio
    Scarfone, Giovanna
    Raspagliesi, Francesco
    Mangili, Giorgia
    Danese, Saverio
    Scollo, Paolo
    Lo Russo, Domenica
    Villa, Antonella
    Aimone, Paola Daniela
    Scambia, Giovanni
    EUROPEAN JOURNAL OF CANCER, 2010, 46 (16) : 2905 - 2912
  • [42] Prognostic Impact of Concomitant p53 and PTEN on Outcome in Early Stage (FIGO I-II) Epithelial Ovarian Cancer
    Skirnisdottir, Ingiridur
    Seidal, Tomas
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2011, 21 (06) : 1024 - 1031
  • [43] Homologous recombination deficiency in newly diagnosed FIGO stage III/IV high-grade epithelial ovarian cancer: a multi-national observational study
    Morgan, Robert D.
    Clamp, Andrew R.
    Barnes, Bethany M.
    Timms, Kirsten
    Schlecht, Helene
    Yarram-Smith, Laura
    Wallis, Yvonne
    Valganon-Petrizan, Mikel
    MacMahon, Suzanne
    White, Rhian
    Morgan, Sian
    McKenna, Sarah
    Hudson, Emma
    Tookman, Laura
    George, Angela
    Manchanda, Ranjit
    Sundar, Sudha S.
    Nicum, Shibani
    Brenton, James D.
    Kristeleit, Rebecca S.
    Banerjee, Susana
    McNeish, Iain A.
    Ledermann, Jonathan A.
    Taylor, Stephen S.
    Evans, D. Gareth R.
    Jayson, Gordon C.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2023, 33 (08) : 1253 - 1259
  • [44] Outcomes of fertility-sparing surgery for women of reproductive age with FIGO stage IC epithelial ovarian cancer
    Kashima, Katsunori
    Yahata, Tetsuro
    Fujita, Kazuyuki
    Tanaka, Kenichi
    INTERNATIONAL JOURNAL OF GYNECOLOGY & OBSTETRICS, 2013, 121 (01) : 53 - 55
  • [45] Risk stratification of abdominopelvic failure for FIGO stage III epithelial ovarian cancer patients: implications for adjuvant radiotherapy
    Chang, Jee Suk
    Koom, Woong Sub
    Kim, Sang Wun
    Kim, Sunghoon
    Kim, Yong Bae
    Kim, Young Tae
    Kim, Gwi Eon
    JOURNAL OF GYNECOLOGIC ONCOLOGY, 2013, 24 (02) : 146 - 153
  • [46] Speculation on optimal numbers of examined lymph node for early-stage epithelial ovarian cancer from the perspective of stage migration
    Li, Yuan
    Ding, Jiashan
    Zheng, Huimin
    Xu, Lijiang
    Li, Weiru
    Zhu, Minshan
    Zhang, Xiaolu
    Ma, Cong
    Zhang, Fangying
    Zhong, Peiwen
    Liang, Dong
    Han, Yubin
    Zhang, Siyou
    He, Linsheng
    Li, Jiaqi
    FRONTIERS IN ONCOLOGY, 2023, 13
  • [47] Tomm34 is commonly expressed in epithelial ovarian cancer and associates with tumour type and high FIGO stage
    Muller, Petr
    Coates, Philip J.
    Nenutil, Rudolf
    Trcka, Filip
    Hrstka, Roman
    Chovanec, Josef
    Brychtova, Veronika
    Vojtesek, Borivoj
    JOURNAL OF OVARIAN RESEARCH, 2019, 12 (1)
  • [48] Influence of Residual Tumor on Outcome in Ovarian Cancer Patients With FIGO Stage IV DiseaseAn Exploratory Analysis of the AGO-OVAR (Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group)
    Pauline Wimberger
    Michael Wehling
    Nils Lehmann
    Rainer Kimmig
    Barbara Schmalfeldt
    Alexander Burges
    Philipp Harter
    Jacobus Pfisterer
    Andreas du Bois
    Annals of Surgical Oncology, 2010, 17 (6) : 1642 - 1648
  • [49] Tomm34 is commonly expressed in epithelial ovarian cancer and associates with tumour type and high FIGO stage
    Petr Muller
    Philip J. Coates
    Rudolf Nenutil
    Filip Trcka
    Roman Hrstka
    Josef Chovanec
    Veronika Brychtova
    Borivoj Vojtesek
    Journal of Ovarian Research, 12
  • [50] Residual tumor and primary debulking surgery vs interval debulking surgery in stage IV epithelial ovarian cancer
    Sorensen, Sarah Mejer
    Hogdall, Claus
    Mosgaard, Berit Jul
    Dalgaard, Maya Isabella Riise
    Jensen, Mai Partridge
    Fuglsang, Katrine
    Schnack, Tine Henrichsen
    ACTA OBSTETRICIA ET GYNECOLOGICA SCANDINAVICA, 2022, 101 (03) : 334 - 343